[A21-117] Roxadustat (anaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 15.12.2021
Project no.:
A21-117
Commission:
Commission awarded on 06.09.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Adults with symptomatic anaemia associated with chronic kidney disease (CKD) who were not previously treated with an erythropoiesis-stimulating agent (ESA) or who are converting from an ESA (conversion of adults with stable ESA pretreatment only when there is a medical indication for a treatment switch)
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.